TABLE 1.

Cohort Demographics

	HIV + COVID	COVID	P
Sample size	20	41
Age*	52 (30–76)	65 (25–93)	0.001§
Sex†			0.319
Female	9 (45%)	24 (59%)
Male	11 (55%)	17 (42%)
Race†			0.796
AA	12 (60%)	26 (63%)
W	8 (40%)	15 (37%)
Days postsymptom onset*	7 (1–20)	4 (0–16)	0.052
Disease severity†,‡			<0.001§
Nonhospitalized	12 (60%)	5 (12%)
Mild-moderate illness	1 (5%)	23 (56%)
Severe illness	6 (30%)	7 (17%)
Deceased	1 (5%)	6 (15%)
Comorbidities†
Hypertension	16 (80%)	34 (83%)	>0.999
Obesity	9 (45%)	21 (51%)	0.786
Diabetes	7 (35%)	22 (54%)	0.187
COPD	6 (30%)	8 (20%)	0.518
Cancer	4 (20%)	8 (20%)	>0.999
ART regimen
NRTI	19 (95%)
NNRTI	0 (0%)
PI	4 (20%)
INSTI	18 (90%)
CD4
Percent	32% (13%–45%)
Count	729 (181–1619)

Statistical analysis was performed for each category.

^*Mann–Whitney U test.

^†Fisher exact test.

^‡Analysis compared frequency of nonhospitalized with hospitalized individuals.

Percentages were rounded to the nearest whole number.

AA, African American; COPD, chronic obstructive pulmonary disease; INSTI, integrase strand transfer inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; W, White.

^§p ≤ 0.05.